Human Papilloma Virus Infection Type 16
9
2
3
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
33%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
Development of a Self-collection Device for Cervical Cancer Screening
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3
Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts